HTG Molecular Diagnostics (NASDAQ:HTGM) had its price objective trimmed by HC Wainwright from $8.00 to $4.00 in a research report released on Wednesday, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the medical research company’s stock.
Other equities research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a buy rating to a hold rating in a research report on Tuesday, July 16th. Canaccord Genuity reaffirmed a buy rating and issued a $5.00 price objective on shares of HTG Molecular Diagnostics in a research report on Tuesday, May 14th. Finally, ValuEngine raised shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $5.20.
HTGM stock traded down $0.07 during trading on Wednesday, reaching $1.11. The stock had a trading volume of 556,635 shares, compared to its average volume of 207,613. HTG Molecular Diagnostics has a one year low of $1.04 and a one year high of $5.46. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.49 and a quick ratio of 6.05. The stock has a 50 day moving average price of $1.50. The stock has a market cap of $36.74 million, a P/E ratio of -1.85 and a beta of 1.55.
Several institutional investors have recently added to or reduced their stakes in HTGM. Jane Street Group LLC bought a new position in shares of HTG Molecular Diagnostics during the 4th quarter valued at approximately $27,000. Cowen Prime Services LLC bought a new position in shares of HTG Molecular Diagnostics during the 1st quarter valued at approximately $50,000. Millennium Management LLC bought a new position in shares of HTG Molecular Diagnostics during the 4th quarter valued at approximately $151,000. BlackRock Inc. grew its position in shares of HTG Molecular Diagnostics by 16.4% during the 4th quarter. BlackRock Inc. now owns 88,565 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 12,448 shares during the period. Finally, TD Asset Management Inc. grew its position in shares of HTG Molecular Diagnostics by 4.9% during the 1st quarter. TD Asset Management Inc. now owns 98,164 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 4,600 shares during the period. 44.98% of the stock is owned by hedge funds and other institutional investors.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Featured Story: The components of the Stochastic Momentum Index
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.